From March 19 to 22, i-SENS participated in the Advanced Technologies & Treatments for Diabetes 2025 (ATTD 2025) in Amsterdam, Netherlands. We were able to boost brand awareness in Europe and further expand our presence in the global market by engaging with a wide range of international visitors.
At this year’s event, we presented a full lineup of point-of-care diagnostic solutions-including immunoassay, blood gas, and electrolyte analyzers, as well as the CareSens® Air, our continuous glucose monitoring (CGM) system that officially entered global markets this year and blood glucose meters.
We also previewed a mediaal video of the upgraded CareSens Air—drawing strong interest from visitors. The new version allows for optional calibration, meaning users only need to do a fingertip blood test when they feel it’s necessary. The upgrade has improved flexibility and convenience in glucose management. Also, the sensor warm-up time has been dramatically reduced from 2 hours to just 30 minutes, enabling users to begin tracking their glucose much faster. This improvement supports more responsive and structured diabetes care.
We also introduced an app for smartwatch, which lets users easily view glucose readings directly on devices like Galaxy Watch or Apple Watch—especially useful when hands are tied (e.g., working out, driving). These features are now available by updating the CareSens Air app on Google Play or the Apple App Store.
Having successfully launched CareSens Air in 14 countries—including Germany, UK, Netherlands, Iran, Algeria, Morocco, Finland, and Belgium—i-SENS used the ATTD 2025 platform to highlight the unique advantages of our products and reinforce our role as a global player in diabetes care.
With CE approval for the upgraded CareSens Air granted on March 25, we’re more motivated than ever to expand into new markets and participate in global conferences to share our innovations and user-centered solutions with the world.